Great discussion last night with the #EMPEROR in the room
Thanks @JavedButler1 @DrNasrien @hswapnil & Dr. Bayes
If you want to view the recording the link is here:
drive.google.com/file/d/10iTYIN…
We started with @hswapnil disclosing his #flozinator status & how we all need to be as well
@hswapnil showed that until now for CKD, every trial of other drugs has essentially failed.
Although renal function was not a 10 (or 2o or even 3o) endpoint of EMPA trials, the benefits were seen
Work by @ChristosArgyrop (🥬Lover & #Flozinator) showed Renal & CVD benefits #SGLT2i
@hswapnil @uOttawa mentioned that mechanism of how renal protection with #SGLT2i occurs unknown. But asked the proactive question: "Does it Matter?"...and now he is a cardiologists according to @JavedButler1
Group Hug Endo/Cards/Nehpro
@DBelardoMD @DLBHATTMD @ChristosArgyrop
@DrNasrien presented a great overview of the treatment of #heartFailure & Future directions.
Emphasized the 4 pillars of treatment & also why/how we need to optimize dosing of #HF therapy quickly, rather than stepwise- delaying the benefits.
#HeartSuccess #FunctionNotFailure
@JavedButler1 presented #EMPERORPreserved and its implications
🫀 21% ⬇️ in Primary Endpoint for #SGLT2i vs placebo
🫀 Context placed in terms of other studies in #HFpEF: 1st drug with +ve outcome even if driven by HF hospitalizations
To date, we have no tx & 🏥major issue
@JavedButler1 discussed the renal findings related to LVEF in #EMPERORPreserved, specifically the renal endpoints used in this study: Will wait for more on this topic as more publications come from this trial.
Thanks to all our amazing speakers! @VietHeartPA @SKhanMHCM
To watch the recording it is now on @YouTube at
Share this Scrolly Tale with your friends.
A Scrolly Tale is a new way to read Twitter threads with a more visually immersive experience.
Discover more beautiful Scrolly Tales like this.